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The World Health Organization (WHO) estimates that 40% of tuberculosis (TB)
cases are not diagnosed and treated correctly. Even though there are several
diagnostic tests available in the market, rapid, easy, inexpensive detection, and
drug susceptibility testing (DST) of Mycobacterium tuberculosis is still of critical
importance specially in low and middle-income countries with high incidence of the
disease. In this work, we have developed a microscopy-based methodology using the
reporter mycobacteriophage mCherrybombφ for detection of Mycobacterium spp. and
phenotypic determination of rifampicin resistance within just days from sputum sample
collection. Fluoromycobacteriophage methodology is compatible with regularly used
protocols in clinical laboratories for TB diagnosis and paraformaldehyde fixation after
infection reduces biohazard risks with sample analysis by fluorescence microscopy.
We have also set up conditions for discrimination between M. tuberculosis complex
(MTBC) and non-tuberculous mycobacteria (NTM) strains by addition of p-nitrobenzoic
acid (PNB) during the assay. Using clinical isolates of pre-XDR and XDR-TB strains
from this study, we tested mCherrybombF for extended DST and we compared the
antibiotic resistance profile with those predicted by whole genome sequencing. Our
results emphasize the utility of a phenotypic test for M. tuberculosis extended DST. The
many attributes of mCherrybombF suggests this could be a useful component of clinical
microbiological laboratories for TB diagnosis and since only viable cells are detected this
could be a useful tool for monitoring patient response to treatment.
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INTRODUCTION
There are substantial advances in diagnosis and treatment of
tuberculosis (TB), but this disease remains a significant global
health threat (Sulis et al., 2016). The World Health Organization
(WHO) estimates that 40% of TB cases go undiagnosed and
consequently not treated (Glaziou et al., 2013; López-Hernández
et al., 2016). In 2016, WHO recommended the use of rapid
molecular tests to speed up TB drug susceptibility testing
(DST) (WHO, 2016) although due to the cost of equipment
and supplies, Ziehl Neelsen staining of Mycobacterium spp. in
sputum, with subsequent culture to determine viable bacilli
and DST using the proportion method is often the method of
choice. Culture methodology is laborious and takes 3–6 weeks
to report the presence of viable mycobacteria in the sample
and a few additional weeks for DST (Naveen and Peerapur,
2012).
Mycobacteriophages are viruses that efficiently and specifically
infect Mycobacterium spp., and provide tools for genetic
analysis and clinical control of TB (Hatfull, 2010, 2012).
Several phage-based diagnostic approaches have been described,
including the commercially developed phage amplification
biological assay (FASTPlaqueTM) utilizing M. tuberculosis-
dependent reproduction of phage D29 and plaque formation on
the fast-growing Mycobacterium smegmatis (Wilson et al., 1997;
Watterson et al., 1998). The FASTPlaque assay has been adapted
for determining resistance to rifampicin and other antibiotics
commonly used for TB treatment (Albert et al., 2001).
An alternative luciferase reporter phage assay uses
recombinant mycobacteriophages carrying the firefly luciferase
gene to detect M. tuberculosis by luminescence, coupled with
empirical determination of drug resistance by light emission
in the presence of antibiotic (Jacobs et al., 1993). These phages
provide a simple and rapid assay, but are not well-suited
to detection of partially resistant cultures; they also require
the propagation of live potentially infectious cultures, and
the level of sensitivity in laboratory grown cultures has yet
to be fully replicated with clinical specimens (Eltringham
et al., 1999; Banaiee et al., 2001; Dinnes et al., 2007; WHO,
2017).
Fluoromycobacteriophages are reporter phages containing a
fluorescent reporter gene such as gfp or ZsYellow (Piuri et al.,
2009) and has potential for rapid diagnosis and DST of TB clinical
isolates (Rondón et al., 2011). These phages are thermosensitive
and do not lyse cells at 37◦C, and in consequence, fluorescent
mycobacterial cells can be readily detected by fluorescence
microscopy or flow cytometry. Recently, we described the
construction of a second generation fluoromycobacteriophage,
mCherrybombφ, with optimized expression of a mCherrybomb gene
in mycobacteria with improved fluorescent signal and shorter
time to detection of M. tuberculosis using fluorimetry (Urdániz
et al., 2016).
The current fluoromycobacteriophages are derived from
phage TM4, a broad host range phage that can infect several
Mycobacterial species including, M. tuberculosis, M. bovis,
M. smegmatis, and atypical Mycobacteria (Ford et al., 1998). They
can rapidly and easily reveal the metabolic state of M. tuberculosis
and consequently report its response to antibiotics (Piuri et al.,
2009; Rondón et al., 2011), and have potential advantages
over existing phage-based TB diagnostic methods. Notably,
after reporter phage infection, cells can be fixed using
paraformaldehyde allowing safe manipulation of the sample
and preservation of the fluorescence (Piuri et al., 2009; Jain
et al., 2012; Yu et al., 2016). Fluorescence microscopy provides
for simple sample analyses, and low-cost LED (light emitting
diode) fluorescence adapters facilitate the use of fluorescence
microscopy in developing countries (Anthony et al., 2006; Marais
et al., 2008). Moreover, Breslauer et al. (2009) described the use
of a mobile phone-mounted fluorescence microscope with LED
excitation with potential for imaging M. tuberculosis-infected
samples.
Next generation sequencing and our understanding of the
genetic basis of antibiotic resistance has led to the development
of rapid genotypic TB tests (Cole et al., 1998; Brossier et al.,
2017). These methods can offer high sensitivity, even for
paucibacillary samples, and do not require culture (Garberi
et al., 2011; Teo et al., 2011; Mboowa et al., 2014; Rufai et al.,
2014; Faksri et al., 2015; Sales et al., 2015; Rahman et al.,
2016). Xpert and MTBDR-plus allow detection of M. tuberculosis
and determination of rifampicin resistance (RIFR) directly in
sputum samples within hours, and is recommended by the
World Health Organization (WHO, 2011; Ocheretina et al., 2014;
Rahman et al., 2016). However, this technology may still be
cost prohibitive in countries with moderate to high incidence
of TB, limiting its application to samples from patients with
risk factors associated to the disease or presumptively carrying
M. tuberculosis resistant strains (Blakemore et al., 2010; Teo
et al., 2011; WHO, 2011; Chang et al., 2012; Rufai et al., 2014;
Rahman et al., 2016). In addition, some discrepancies remain
between genotypic and phenotypic tests (Ocheretina et al., 2014;
Mokaddas et al., 2015; Gurbanova et al., 2017), and at least
in some clinical isolates, resistance cannot be explained by the
presence of known gene mutations (Hazbón, 2004; Louw et al.,
2009).
Here, we report evaluation of the new mCherrybombφ for
detection of M. tuberculosis and rifampicin resistance in sputum
samples from presumptive TB patients in Buenos Aires city.
Also, using fluorescence microscopy for detection, we evaluated
the use of p-nitrobenzoic acid (PNB) for selective inhibition
of members of the M. tuberculosis complex (MTBC) (Sharma
et al., 2010; Shakoor et al., 2010) to distinguish MTBC from
atypical or non-tuberculous mycobacteria (NTM). Additionally,
we established conditions for determination of susceptibility to
other antibiotics that discriminate between multi-drug resistant
TB (MDR-TB), strains wich are resistant to rifampicin and
isoniazid; extremely drug resistant TB (XDR- TB), resistant to
rifampicin, isoniazid, plus any fluoroquinolone and an injectable
drug, kanamycin, amikacin or capreomycin, or pre-XDR wich
show resistance to rifampicin, isoniazid and a fluoroquinolone or
an injectable drug. Whole genome sequencing (WGS) of XDR-
TB strains identified in this study allowed comparison between
phenotypic and genotypic results, and underscore the importance
of rapid methods that evaluate phenotypic resistance in clinical
isolates.
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MATERIALS AND METHODS
Study Population
Two hundred and eighty-three adult presumptive TB patients,
treatment-naive, under antibiotic treatment or that were
previously treated admitted at Laboratorio de Bacteriología
de Tuberculosis, Instituto de Tisioneumonología Dr. Raul
Vaccarezza, Hospital Muñiz, Ciudad Autónoma de Buenos Aires,
Argentina were included in the study. All the participants signed
written informed consent forms, previously approved by the
Ethics Committee of Instituto Vaccarezza, to participate. The
study included adult patients of different nationalities (mostly
Argentinean and from neighboring countries) and gender, with
different classifications at the time of sample taking: treatment-
naive, under treatment, discontinued treatment, relapsed,
treatment failure, etc. Only pulmonary samples were analyzed.
Sputum Samples
Sputum samples were collected in a sterile container and
decontaminated using a modified Petroff protocol. Briefly,
after addition of one volume of 4% NaOH the sample was
incubated at room temperature for 15 min. After incubation,
it was centrifuged for 20 min, the supernatant was discarded,
and the pellet was neutralized to pH 7 by dropwise addition
of 15% H2SO4. The pellet was washed and resuspended
with distilled water. The pellet was used for routine tests
performed in Laboratorio de Bacteriología de la Tuberculosis,
including Ziehl Neelsen stain (Weldu et al., 2013) inoculation
on Löwenstein Jensen (LJ) media for detection and colony
counting of mycobacteria and inoculation on Stonebrink media
(LJ supplemented with 2% sodium pyruvate) for detection
of M. bovis (Daza Bolaños et al., 2017). Only for samples
of patients at high-risk of developing TB disease an aliquot
was used for analysis with MGIT 960 (Martin et al., 2009).
Finally, the remnant of the pellet was used to test with
mCherrybombφ.
Preparation of Stocks of mCherrybombφ
In this study, we used the second generation
fluoromycobacteriophages, carrying an mCherrybomb gene
with optimized expression in mycobacteria (Urdániz et al., 2016).
Stocks of mCherrybombφ were prepared as previously described
(Rondón et al., 2011).
Evaluation of mCherrybombφ for
Detection and Determination of RIF
Susceptibility of Mycobacterium spp.
Remnant pellets of processed sputum samples were resuspended
in 400 µl of Middlebrook 7H9 broth supplemented with OADC
Enrichment (Becton, Dickinson and Company, Sparks, MD,
United States) and PANTA (Becton, Dickinson and Company,
Sparks, MD, United States) and divided in four 100 µl aliquots.
In two aliquots, 4 µg/ml RIF was added and the other two
were kept as control. Samples were recovered for 48 or 96 h
and infected overnight with 5 µl of a stock of mCherrybombφ
(1010–1011 PFU/ml). After that, samples were fixed with 2%
paraformaldehyde for 2 h at room temperature, centrifuged and
the pellet was resuspended in 10 µl of phosphate buffered saline
(PBS) and examined by fluorescence microscopy using 1,000×
magnification. The criterion for detection was the presence of at
least one fluorescent bacillus per 100 fields in the control samples
and for determination of RIF resistance was the same in RIF
treated samples. We also compared the results using the criterion
of two fluorescent bacilli per 100 field but we did not observed
significantly differences between both criteria so we opted for the
first one. Detection results using mCherrybombφ were compared
with growth and colony counting (CFU) in LJ media and
determination of RIF susceptibility with the proportion method
(Canetti et al., 1963).
Microscopy and Settings
A fluorescence microscope (Axiostar Plus; Carl Zeiss) with a
100× objective with oil immersion and phase contrast was used.
Fluorescence images were acquired using a Cannon EOS Rebel
T3 and the software provided with the camera. For detection
of fluorescent mCherrybomb the 64 HE mPlum shift free (E)
filter (EX BP 587/25, BS FT605, EM BP 647/70) (Carl Zeiss)
was used. When necessary, image processing was performed
using Adobe Photoshop CS2 (Adobe Systems Incorporated), but
maintaining identical brightness and contrast settings for all
images.
Evaluation of PNB to Discriminate
Between Mycobacteria of the MTBC
and NTM
Clinical isolates from sputum samples positive for
Mycobacterium spp. and further identified as NTM were
inoculated in Middlebrook 7H9 broth supplemented with
OADC and grown to exponential phase. At least two clinical
isolates identified as M. tuberculosis were also used as controls.
Two culture aliquots of 100 µl were incubated with 500 µg/ml
of PNB for 24 and 48 h and one aliquot was kept as control.
After incubation, samples were centrifuged and the pellet was
resuspended in the same media. Samples were infected overnight
at 37◦C with mCherrybombφ at an approximate multiplicity of
infection (MOI) of 100. Samples were processed as described
above and observed by fluorescence microscopy.
Extended Antibiotic Susceptibility
Testing of Pre-XDR and XDR-TB Clinical
Isolates Using mCherrybombφ
Four M. tuberculosis strains isolated from sputum samples
used in this study, that tested positive for Mycobacterium
and were RIFR with mCherrybombφ, were further identified
as pre-XDR and XDR-TB using the proportion method. To
determine the antibiotic resistance profile of these strains
using our fluoromycobacteriophage methodology, 200 µl of
an exponentially growing culture were preincubated for 24 h
with the following antibiotics: isoniazid (0.2 µg/ml), rifampicin
(4 µg/ml), streptomycin (2 µg/ml), ofloxacin (10 µg/ml),
ethambutol (5 µg/ml), amikacin (1 µg/ml), kanamycin (2.5
µg/ml) and further infected overnight with mCherrybombφ at
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an approximate MOI of 100. After incubation, samples were
processed as described above and observed by fluorescence
microscopy.
DNA Isolation of Pre-XDR and XDR-TB
Strains
Colonies from LJ media were used for DNA extraction. The
protocol for isolation of DNA is described in van Soolingen
et al. (1991). Prior to sequencing the integrity of the DNA was
evaluated by gel electrophoresis (van Soolingen et al., 1991).
Bioinformatics Analysis of Sequenced
Strains
Paired end reads from the four strains analyzed were obtained
using a whole-genome shotgun strategy with a MiSeq, Illumina
at the Instituto Malbrán, Buenos Aires, Argentina. Sequence
reads were checked for quality using FastQC version v0.11.5
(Andrews, 2011) and processed with the PRINSEQ lite version
0.20.4 (Schmieder and Edwards, 2011) for sequence read quality
assessment.
All the reads were deposited in GenBank NCBI Bioproject
PRJNA438689 with the following accession numbers: 152748
(ID: 8724044, 8724043), 161109 (ID: 8724038, 8724037),
156324 (ID: 8724040, 8724039), and 16138 (ID: 8724042,
8724041).
Subsequently reads were aligned to the H37Rv reference
genome (NCBI access number NC_000962.3) using BWA (Li
and Durbin, 2010) and variant calling was made with GATK
(Mckenna et al., 2010). Resulting variants were annotated with
SnpEff (Cingolani et al., 2012) and compared with previously
reported drug resistance-associated variants listed in TBDREAM
database (Sandgren et al., 2009). Each match was classified
using the following criteria: (I) Position match, I(a): Exact
match: the variant in the strain is exactly the same that
the reported in TBDREAM. I(b) Partial match: the variant
in the strain is in the same position that the reported in
TBDREAM but present a different nucleotide. (II) Gene match:
the strain has a variant in a gene reported in TBDREAM,
but it is in different position. (III) No match. Analysis of
the genes containing variants was performed with TuberQ
database (Radusky et al., 2014). When we were not able
to find a gene variant in TBDREAM that could explain
the antibiotic resistant phenotype, we manually inspected
other genes that have been previously reported in resistant
isolates.
On the other hand, a short phylogenetic analysis was
performed between the samples mentioned above and samples
that were previously reported as M, Ra and Beijing sublineages
downloaded from NCBI SRA: ERR760768, ERR776666, and
SRR5314268, respectively. Isolates reads were processed using
the variant calling pipeline mentioned above. At last, resulting
variants from all samples were combined in a single VCF using
GATK and a dendrogram was built using VCFKit (Cook and
Andersen, 2017) with UPGMA algorithm using Beijing sample
as outgroup. Figure 4 was built using ETE Toolkit (Huerta-cepas
et al., 2016).
Statistical Analysis
Data analysis for calculation of sensitivity, specificity, and
predictive values was performed using the R language (The R
Foundation, 2018), and the exact 95% confidence intervals were
estimated using the Hmisc library. To compare the performance
of mCherrybombφ and culture growth in LJ media for detection of
Mycobacterium spp. we employed box and whisker plots.
To evaluate the correlation of mCherrybombφ based detection
and Mycobacterium spp. growth in LJ we applied generalized
linear models using the negative binomial distribution. When
needed multiple comparisons were performed by fitting a
negative binomial models to each pair of categories of growth
in LJ media using the MASS (Venables and Ripley, 2002)
library for R, and adjusting the p-values with the Bonferroni
correction. χ2 goodness of fit tests showed data corresponded
to the negative binomial (in contrast, when a Poisson model was
used this test showed a poor fitting). When needed, incidence rate
ratios (IRRs) were calculated as the exponential of the model’s
coefficient.
RESULTS
Detection of Mycobacterium spp. in
Sputum Samples With mCherrybombφ
We evaluated the performance of mCherrybombφ to detect
the presence of Mycobacterium spp. and determination of
RIF resistance in the remnant of 283 sputum samples from
presumptive TB patients, treatment-naive, previously treated
for TB or under antibiotic treatment for TB. The patient
population enrolled in this study is described in Table 1. Sputum
samples were processed, and part of the pellet was used for
routine diagnostic tests and the remnant was used for testing
with the fluoromycobacteriophage methodology. The bacteria-
containing pellet was recovered in rich media for 48 or 96 h and
infected with mCherrybombφ in the presence or absence of RIF.
Samples were fixed with paraformaldehyde, spun down and 100
fields were examined by fluorescence microscopy. The complete
protocol is schematized in Figure 1. A representative image of
a processed sputum sample recovered for 48 h and infected
with mCherrybombφ or mock infected is shown in Figures 2A,B.
A sample was considered RIF sensitive if fluorescent bacilli were
detected in the control sample and fluorescence was lost in the
presence of RIF. On the contrary, if fluorescent bacilli were
observed in the presence of RIF, the sample was considered
resistant to the drug. The sensitivity, specificity, positive and
negative predictive values of the bacteriophage method were
calculated in comparison to culture in LJ for detection of
Mycobacterium spp., or the proportion method for determination
of RIF resistance, respectively. The results are summarized in
Tables 2, 3.
For detection of Mycobacterium spp., when the pellet was
recovered for 48 h before infection with mCherrybombφ, 67.84%
(192 samples) were concordant between both methods and
32.16% (91 samples) were not detected by mCherrybombφ but
cultured positive in LJ media. An increase in the recovery time
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TABLE 1 | Demographic and clinical characteristics of enrolled participants.
Characteristics Description TB patients∗ (% total)
Gender Male 167 (59)
Female 114 (40.3)
Transgender 2 (0.7)
Age Median (range years) 34









Previous TB treatment 56 (19.79)
In treatment 150 (53)
Unknown 37 (13.08)
Acid-Fast Bacilli (AFB) Negative 86 (30.39)
Positive 197 (69.61)
Culture Status (−) negative 96 (33.9)
(+) 1–19 colonies 20 (7.1)
(++) 20–100 colonies 63 (22.3)




∗Presumptive TB patients, under treatment or with any previous treatment.
to 96 h prior infection improved the detection to 94.35% (267
samples) consistent with both methods. Only 6% of the samples
were discordant: 15 tested positive by culture but negative with
mCherrybombφ and 1 was positive by phage and negative by
culture (Table 2A).
Overall, the sensitivity of mCherrybombφ for detection of
Mycobacterium spp. was 51.36% and 91.98% after 48 and
96 h of recovery, respectively, and the specificity was 100%
and 98.96% (Table 2B). The high specificity was expected
because fluoromycobacteriophages can only infect bacteria of
the genera Mycobacterium. This is a notable advantage of the
method because fluorescentMycobacterium bacilli could be easily
detected by microscopy even in the presence of other genera
contaminants in the sample (Figure 2C).
As shown in Table 2B, in acid- fast bacilli (AFB) smear-
positive patients the sensitivity and specificity were 93.41% and
93.33%, respectively, after recovery for 96 h. The sensitivity in the
86 AFB smear- negative samples was only 40% after 96 h, but it is
worth noting that from these samples only five were positive by
culture and two of them tested positive with mCherrybombφ.
Interestingly, for HIV positive patients [that represent 22.61%
of the study population and are known to be paucibacillary
(Madico et al., 2016; Fan et al., 2017)] the sensitivity and
specificity after 96 h reached 97.3% and 100%, respectively.
When the performance of mCherrybombφ for detection of
Mycobacterium spp. was calculated for treatment-naive patients
or patients previously treated for TB, the values after 96 h of
recovery were between 94.87 and 100% for sensitivity and 100%
for specificity.
When the same analysis was performed for patients that were
currently under antibiotic treatment both parameters drop to
FIGURE 1 | Schematic representation of the protocol for infection with
mCherrybombφ in processed sputum samples.
89.25% for sensitivity and 96.55% for specificity after a recovery
time of 96 h. From the 15 samples that tested positive by culture
and negative by phage (Table 2A), 13 corresponded to these
groups of patients.
Because fluoromycobacteriophages only infect viable cells that
are metabolically active, a likelier explanation for this lower
sensitivity is that even after recovery of the sputum sample for
96 h the cells were not in a physiological state to promote
mCherrybomb expression. Alternatively, because we only have
access to the remnant of the processed sputum sample, the
number of bacteria could be very low in these samples below the
level of detection. The reference method used for comparison was
culture in LJ medium, which provides all the requirements for
optimal growth of mycobacteria, and the time of incubation (30–
40 days) allows recovery of bacilli originally present in the sputum
sample.
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FIGURE 2 | mCherrybombφ infection of processed sputum samples.
(A) Fluorescent bacilli can be observed on top of tissue debris, (B) not
background fluorescence signal is observed in a mock infected control,
(C) fluorescent bacilli can be easily discriminated in a sample contaminated
with coccobacilli. Magnification 100×. Left panel: phase contrast images,
right panel: fluorescence micrograph images.
Finally, since we could not discard that Mycobacteria present
in those 15 discordant samples were phage resistant, we further
prepared liquid cultures from the colonies isolated in LJ media
and infected them with mCherrybombφ. In all samples we
visualized bright red fluorescent cells (data not shown) discarding
that were phage resistant bacteria.
Determination of RIF Resistance With
mCherrybombφ in Sputum Samples
Then, we evaluated the performance of mCherrybombφ to
determine susceptibility to RIF. Out of the 283 samples assessed,
16 were identified as RIFR according to the reference method
(Table 3A).
When we used mCherrybombφ to determine susceptibility to
RIF after a recovery time of 48 h, five samples were identified as
RIFR with mCherrybombφ. In 96.11% of the cases (272 samples)
the results for RIF susceptibility were consistent between both
methods and in 3.89% (11 samples) were discordant. When
recovery time was extended to 96 h, the 16 RIFR samples tested
positive with the fluoromycobacteriophage method; the results
were congruent for 99.29% of the cases (281 samples) and only
0.71% (2 samples) were discordant (Table 3A).
Among the samples determined as RIFR, four isolates were
identified a posteriori as XDR-TB and pre-XDR-TB (see below),
illustrating the importance of early detection of resistance to this
antibiotic.
Altogether, the sensitivity, specificity and predictive values
of mCherrybombφ to detect rifampicin resistance compared to
the proportion method are summarized in Table 3B. While the
specificity was 100% after recovery for 48 and 96 h, sensitivity
highly improved from 31.25%, at 48 h, to 100% when the sample
was recovered for 96 h (Table 3B).
As can be seen from Table 3B, the specificity for detection of
rifampicin resistance in all the groups of patients was 100% after
recovery for 48 or 96 h.
In AFB smear-positive patients the sensitivity for rifampicin
resistance detection reached 100% after recovery for 96 h.
The sensitivity in AFB smear- negative samples could not be
calculated because none of these samples were RIFR.
In HIV positive and negative patients 100% sensitivity was
obtained after recovery for 96 h. Once again, sensitivity could not
be calculated for treatment-naive patients because none of them
carried RIFR strains. For patients under treatment or previously
treated for TB, sensitivity highly improved to 100% when cells
were recovered for 96 h before infection with mCherrybombφ.
Overall, it was clear that an extended recovery time was
crucial to increase the sensitivity of the fluoromycobacteriophage
methodology to determine susceptibility to this first line
antibiotic.
Correlation Between the Number of
Bacilli Detected With mCherrybombφ and
the Number of CFU Present in the
Sample
One advantage of phenotypic versus genotypic tests is that can
discriminate between viable and non-viable cells. This is a key
feature for a test intended to monitor patient’s response to
antibiotic treatment. Fluoromycobacteriophages can develop a
fluorescent signal only in metabolically active cells. As shown
in Figure 3 there is a direct correlation between the number
of colonies in LJ and the number of fluorescent bacilli detected
by the fluoromycobacteriophage method. When samples were
recovered for 48 h before infection, a very low number of
fluorescent bacilli (López-Hernández et al., 2016; Sulis et al.,
2016) were detected for a colony count between 20 and
100, but this amount increased to 13–27 bacilli per hundred
fields when the CFU were more than 100 or uncountable
(Figure 3A). The number of bacilli detected by mCherrybombφ
notably increased when the recovery time was 96 h and
even for those samples with poor growth in LJ media (1–
19 CFU) we were able to detect an average of 8 bacilli/100
fields with the phage method (Figure 3B) highlighting the
good performance of fluoromycobacteriophages in paucibacillary
samples when enough time is given for recovery prior to
infection.
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TABLE 2 | Results and Performance parameters: mCherrybombφ (8) versus culture in LJ media for detection of Mycobacterium spp.
(A)
No. of isolates
Culture (+) Culture (−)
Condition 8 (+) 8 (−) 8 (+) 8 (−) Total
48 h ≥ 1 96 91 0 96 283
96 h ≥ 1 172 15 1 95 283
(B)
Detection of Mycobacterium spp.
mCherrybomb8 48 h 95% CI mCherrybomb8 96 h 95% CI
All patients 96/283 172/283
Sensitivity 51.36 (43.93–58.70) 91.98 (87.12–95.44)
Specificity 100 (96.23–100) 98.96 (94.33–99.97)
PPV 100 (96.23–100) 99.42 (96.82–99.99)
NPV 51.34 (43.93–58.7) 86.36 (78.51–92.16)
AFB positive 95/197 170/197
Sensitivity 52.2 (44.68–59.64) 93.41 (88.77–96.55)
Specificity 100 (78.20–100) 93.33 (68.05–99.83)
PPV 100 (96.19–100) 99.42 (96.78–99.99)
NPV 14.71 (8.47–23.09) 53.85 (33.37–73.41)
AFB negative 1/86 2/86
Sensitivity 20 (0.51–71.64) 40 (52.74–85.34)
Specificity 100 (95.55–100) 100 (95.55–100)
PPV 100 (2.50–100) 100 (15.81–100)
NPV 95.29 (88.39–98.70) 96.43 (89.92–99.26)
HIV positive 18/64 36/64
Sensitivity 48.65 (31.92–65.60) 97.3 (85.84–99.93)
Specificity 100 (87.23–100) 100 (87.23–100)
PPV 100 (81.47–100) 100 (90.26–100)
NPV 58.7 (43.23–73.00) 96.43 (81.65–99.91)
HIV negative 49/135 93/135
Sensitivity 47.12 (37.25–57.15) 89.42 (81.86–94.60)
Specificity 100 (88.78–100) 100 (88.78–100)
PPV 100 (92.75–100) 100 (96.11–100)
NPV 36.05 (25.97–47.12) 73.81 (57.96–86.14)
Treatment-naive 2/40 4/40
Sensitivity 50 (6.75–93.24) 100 (39.76–100)
Specificity 100 (90.26–100) 100 (90.26–100)
PPV 100 (15.81–100) 100 (39.76–100)
NPV 94.74 (82.25–99.36) 100 (90.26–100)
Previous treatment 21/56 37/56
Sensitivity 53.84 (37.18–69.90) 94.87 (82.67–99.37)
Specificity 100 (80.49–100) 100 (80.49–100)
PPV 100 (83.89–100) 100 (90.51–100)
NPV 48.57 (31.38–66.01) 89.47 (66.86–98.70)
In treatment 61/150 108/150
Sensitivity 50.41 (41.17–59.62) 89.25 (82.32–94.15)
Specificity 100 (88.05–100) 96.55 (82.23–99.91)
PPV 100 (94.13–100) 99.08 (94.99–99.98)
NPV 32.58 (23.02–43.34) 68.29 (51.91–81.92)
(A) Contingency table. (B) The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the fluoromycobacteriophage method were
calculated in comparison to culture in LJ.
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TABLE 3 | Results and Performance parameters: mCherrybombφ (8) versus proportion method in LJ media for determination of RIF resistance.
(A)
No. of isolates
Culture (RIFR) Culture (RIFS)
Condition 8 (RIFR) 8 (RIFS) 8 (RIFR) 8 (RIFS) Total
48 h ≥ 1 5 11 0 267 283
96 h ≥ 1 16 0 2 265 283
(B)
Determination of RIF Resistance
mCherrybomb8 48 h 95% CI mCherrybomb8 96 h 95% CI
All patients 5/283 16/283
Sensitivity 31.25 (11.02–58.66) 100 (79.41–100)
Specificity 100 (98.63–100) 100 (98.63–100)
PPV 100 (47.82–100) 100 (79.41–100)
NPV 96.04 (93.03–98.01) 100 (98.63–100)
AFB positive 5/197 16/197
Sensitivity 31.25 (11.02–58.66) 100 (79.41–100)
Specificity 100 (97.98–100) 100 (97.98–100)
PPV 100 (47.82–100) 100 (79.41–100)
NPV 94.27 (89.98–97.11) 100 (97.98–100)
AFB negative 0/86 0/86
Sensitivity ND ND ND ND
Specificity 100 (95.80–100) 100 (95.80–100)
PPV ND ND ND ND
NPV 100 (95.80–100) 100 (95.80–100)
HIV positive 2/64 4/64
Sensitivity 50 (6.76–93.24) 100 (39.76–100)
Specificity 100 (94.04–100) 100 (94.04–100)
PPV 100 (15.81–100) 100 (39.76–100)
NPV 96.77 (88.83–99.61) 100 (94.04–100)
HIV negative 1/135 9/135
Sensitivity 11.11 (0.28–48.25) 100 (66.37–100)
Specificity 100 (97.11–100) 100 (97.11–100)
PPV 100 (2.50–100) 100 (66.37–100)
NPV 94.03 (88.58–97.39) 100 (97.11–100)
Treatment-naive 0/40 0/40
Sensitivity ND ND ND ND
Specificity 100 (91.19–100) 100 (91.19–100)
PPV ND ND ND ND
NPV 100 (91.19–100) 100 (91.19–100)
Previously treated 2/56 7/56
Sensitivity 28.57 (3.66–70.95) 100 (59.03–100)
Specificity 100 (92.74–100) 100 (92.74–100)
PPV 100 (15.81–100) 100 (59.04–100)
NPV 90.74 (79.70–96.92) 100 (92.75–100)
In treatment 3/150
Sensitivity 37.5 (08.52–75.51) 100 (63.05–100)
Specificity 100 (97.43–100) 100 (97.43–100)
PPV 100 (29.24–100) 100 (63.06–100)
NPV 96.6 (92.24–98.89) 100 (97.44–100)
(A) Contingency table. (B) The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the fluoromycobacteriophage method were
calculated in comparison to proportion method in LJ.
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FIGURE 3 | Correlation between the number of fluorescent bacilli detected with mCherrybombφ and CFU determined by culture in LJ media after recovery of the
sputum samples for 48 h (A) or 96 h (B). Box and whisker plots: the wide bands represents the medians, the boxes the quartiles Q1 and Q3 (percentiles 25th and
75th, respectively) and the whiskers extend to a maximum of 1.5 the interquartile range, beyond which data are represented with individual points.
Discrimination Between Species of the
M. tuberculosis Complex and
Non-tuberculous Mycobacteria
Using PNB
In order to additionally discriminate between MTBC and NTM
using mCherrybombφ, we evaluated the effect of PNB during
the assay. As stated, mCherrybombφ is a derivative of TM4, a
broad host range mycobacteriophage (Riska et al., 1997) thus it
was not surprising that some of the samples testing positive for
Mycobacterium spp. with mCherrybombφ were further identified
as containing M. kansasii, M. szulgai, M. fortuitum, M. abscessus,
and M. avium.
Cultures of M. tuberculosis and atypical mycobacteria were
grown until exponential phase and were preincubated with 500
µg/ml of PNB for 24 h prior to infection with mCherrybombφ.
As shown in Figure 4A, when M. tuberculosis was pretreated
with PNB, no fluorescent bacilli were observed. In contrast,
infection and expression of mCherrybomb was not affected in
the NTM strains tested (Figures 4B–E and data not shown).
These observations suggest that PNB in combination with
fluoromycobacteriophages can be used as a simple way to
distinguish between MTBC and NTM bacteria present in sputum
samples.
Comparison of Performance of
mCherrybombφ DST of Pre-XDR and XDR
Clinical Isolates With Reference Method
and WGS
As we previously mentioned, four clinical isolates identified in
this study as RIFR using mCherrybombφ were further reported as
XDR or pre-XDR-TB in the lab records.
We evaluated the performance of mCherrybombφ for
extended DST. Resistance to isoniazid, streptomycin, ofloxacin,
ethambutol, amikacin, capreomycin, and kanamycin was
assessed using liquid cultures of these clinical isolates and results
were compared to the proportion method.
We also performed WGS of the four isolates and we searched
for mutations in genes reported to confer resistance to the tested
antibiotics. The results obtained for the three methodologies are
summarized in Table 4.
For isoniazid and rifampicin we found a perfect correlation
between both phenotypic methods and we were able to easily
identify mutations that could account for the resistance profile.
Genotypic analysis revealed the presence of the katG S315T
mutation in three isolates and the other presented a kasA
G269S mutation associated to isoniazid resistance (Lee et al.,
1999; Galarza et al., 2014). This strain also had an additional
mutation in katG (P432L) that has not been previously reported
as associated to isoniazid resistance. All RIFR strains had
mutations in rpoB, three corresponded to the well reported S450L
mutation and the other was a change from aspartic acid to valine
in position 435 (D435V) (Eldholm et al., 2015; Datta et al.,
2016).
For streptomycin, we found a good correlation between the
fluoromycobacteriophage and the proportion method and we
were able to identify the gene variants that could be responsible
for the observed phenotype. One of the strains presented a
mutation in the 16S rRNA gene, rrs 516C>T (Dobner et al.,
1997). The other two strains had a frameshift in gidB that is a well-
established determinant of streptomycin resistance (Okamoto
et al., 2007). Moreover, the gidB V110 frameshift was previously
found in 90% of analyzed isolates of the M strain that caused an
outbreak in Argentina in the early 1990s (Eldholm et al., 2015).
Streptomycin was introduced in anti TB regimens in Argentina in
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FIGURE 4 | Fluorescence images of mCherrybombφ infections in presence or absence of p-nitrobenzoic acid (PNB) for differentiation of mycobacteria belonging to
the MTBC and NTM. Magnification 100×. (A) M. tuberculosis; (B) M. smegmatis; (C) M. abscessus; (D) M. kansasii; (E) M. fortuitum. Left panel: phase contrast
images, right panel: fluorescence micrograph images.
TABLE 4 | Phenotypic DST results of pre-XDR and XDR-TB clinical isolates obtained with mCherrybombφ (8) or proportion reference culture method (C).
Strains
Antibiotic 161109 152748 16138 156324
8 C Mutation 8 C Mutation 8 C Mutation 8 C Mutation
INH R R katG S315T R R kasA G269S katG
P432L (NR)
R R katG S315T R R katG S315T
RIF R R rpoB D435V R R rpoB S450L R R rpoB S450L R R rpoB S450L
STR R R rrs 516C>T S S R R gidV110fs R R gidV110fs
EMB R S embC V981L∗ R R embB G406D
embC A774S (NR)
R S embB G406A
embC V981L∗
R R embB G406A
embC V981L∗
KAN R S No mutation R R No mutation R R rrs 1401A>G R R rrs 1401A>G








R R gyrA S95T
gyrA E21Q (NR)
gyrA G688D (NR)
R R gyrA S95T
gyrA E21Q (NR)
gyrA G688D (NR)
Putative mutations that could account for the resistance (Mutation) identified after analysis of whole genome sequencing data are indicated. NR, Mutations not reported
in bibliography as associated to the indicated antibiotic resistance; S, sensitive; R, resistant. ∗Could be S or R depending of the method used for AST.
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FIGURE 5 | Dendrogram based on SNPs between the pre-XDR and XDR
strains isolated in this study (16138, 156324, 161109, and 152748) and
clinical isolates of two of the largest outbreaks in Argentina (M, Ra). Number of
SNPs were calculated using the H37Rv strain as reference, the Beijing strain
was included as out-group. Figures next to each strain indicate number of
unique SNPs.
1946 (de Kantor and Barrera, 2007) so it is important to include
this antibiotic during DST.
Results for ethambutol were more discrepant. Two strains
were sensitive by the reference method and resistant by
mCherrybombφ. The strain 161109 had an embC V981L mutation
that could render the strain sensitive or resistant depending
of the method use for DST (Sreevatsan et al., 1997). Strain
16138 also had an embB G406A mutation in addition to that
but tested sensitive to ethambutol with the proportion method.
Antibiotic susceptibility testing was repeated in this strain, with
the same outcome. This result was unexpected because strain
156324 presented the same gene variants for embB and embC
and was resistant to ethambutol by phage and the proportion
method. It has been previously reported that testing of resistance
to ethambutol can be inconsistent and can lead to ambiguous
results (Madison et al., 2002).
For kanamycin and the other two injectable antibiotics tested,
amikacin and capreomycin (data not shown), we got similar
results for both phenotypic methods with the exception of isolate
161109 that tested sensitive for kanamycin by the reference
method and resistant by the phage method. The sample from
this patient was also tested using MGIT and some bacterial
growth was observed at day 12 in the presence of kanamycin.
This could be indicative of the presence of a mixed population
with the KanR population present in a very low proportion. It
is important to notice that fluoromycobacteriophages can detect
individual cells being particularly useful for detection of partially
resistant cultures even if resistant cells are underrepresented in
the sample. For two of the resistant isolates we identified the
rrs1401A>G mutation associated to kanamycin resistance but for
strain 152748 and also for isolate 161109 we were not able to find
any mutations that could be associated to this phenotype.
All the strains resulted resistant to at least one
fluoroquinolone, either with mCherrybombφ or the reference
method. In all the strains we identified mutations in gyrA
previously reported as associated to fluoroquinolone resistance.
Additionally, all four isolates presented the following mutations:
gyrA E21Q and gyrA G688D but we were not able to find any
reports describing these mutations as responsible for resistance
to fluoroquinolones.
Finally, we performed a phylogenetic analysis in an attempt
to trace these four isolates. For this analysis we constructed a
dendrogram based on SNPs between these strains and clinical
isolates of two of the largest TB outbreaks in Argentina with
available reads at NCBI, ERR760768, and ERR776666, reported
as M (of Haarlem family) and Ra (of LAM- Latin American
Mediterranean family), respectively (Eldholm et al., 2015; Bigi
et al., 2017) (Figure 5). The analysis of the dendrogram shows
that 156324 and 16138 cluster in the same group as the M strain.
However, strain 152748 was closer to Ra than other analyzed
strains. Strain 161109 did not cluster with any of the analyzed
strains.
DISCUSSION
Several phage-based methods have been proposed for TB
diagnosis over time but there are few studies validating their use
in sputum samples (Banaiee et al., 2001; Albert et al., 2004, 2007;
Kiraz et al., 2007; Mole et al., 2007; Zhu et al., 2011; Hemvani
et al., 2012; Jain et al., 2012; O’Donnell et al., 2015).
When we evaluated the performance of mCherrybombφ
compared to the reference method to detect Mycobacterium
spp. in sputum, the sensitivity and specificity after recovering
the sample for 96 h reached values of 91.98 and 98.96%,
respectively.
The most recent work using reporter phages carrying
fluorescent proteins in combination with flow cytometry for
detection in sputum, informed a mean time for results of
7.5 days (range 5–9 days) and a sensitivity and specificity for
M. tuberculosis of 95.90% and 83.33%, respectively (O’Donnell
et al., 2015).
In this work, the high sensitivity and specificity values for
mCherrybombφ were achieved using only part of the processed
sputum sample remaining after its use for routine practices in
the clinical lab, and these parameters are likely to be improved
with access to a standardized sample. However, an advantage of
the study design is that evaluation of fluoromycobacteriophage
technology did not require changes to the routine processing
of samples in the clinical laboratory. Furthermore, fluorescence
microscopy is available in many clinical laboratories, and
fixation of cells with paraformaldehyde reduces biohazard
concerns.
During experimental design, recovery time before infection
was a key parameter as demonstrated by the approximately 40%
increment in sensitivity at 96 h versus 48 h. Even though our
study suggests that optimal results are obtained after recovering
for 96 h, in the practice results for 50% of the samples can
be obtained after just 48 h of recovery (3 days from sputum
collection). This time point should be tested if enough sample is
provided for analysis.
With this experimental set up, in just 3 days from sputum
collection, 49% (18 of 37) of the samples positive by culture from
HIV patients tested positive with the fluoromycobacteriophage
method. After 5 days, 97% (36 of 37) of the samples were detected,
reflecting the usefulness of this technique for TB diagnosis in
paucibacillary samples.
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For determination of rifampicin resistance, the sensitivity
and specificity of mCherrybombφ were both 100%, when the
sample was recovered for 96 h prior to infection. The marked
difference in sensitivity, from 31.25 to 100% when the sample
was recovered for 96 h instead of 48 h, may reflect either a
heterogeneous distribution of bacilli in the sample or the presence
of mixed populations of rifampicin sensitive and resistant
bacteria additionally to the observation that an extended recovery
time can improve the metabolic state and number of viable bacilli
in the sample as explained above.
The high specificity obtained with mCherrybombφ to detect
Mycobacterium spp. was not unexpected because bacteriophages
have a limited host range, mostly restricted to bacteria belonging
to the same genera. The high sensitivity of mCherrybombφ
for detection of mycobacteria and rifampicin resistance was
evidenced by the fact that all the strains in this study that
were RIFR by culture, were identified by mCherrybombφ. In
general terms is crucial that a diagnostic test shows a high
sensitivity, capturing all the active TB patients to implement
the proper treatment and dissemination of resistant strains, but
also a high specificity, as demonstrated for mCherrybombφ, to
avoid uninfected people being exposed to unnecessary and long
treatments with several adverse effects (Salzer et al., 2016; Dobbs
and Webb, 2017).
Because phage mCherrybombφ infects both MTBC and NTM,
and the treatment of such infections is very different (Salzer et al.,
2016; Wassilew et al., 2016), in a standardized sputum sample one
extra aliquot could be directly treated with PNB (Shakoor et al.,
2010) for early distinction between these mycobacteria. We note
that fluoromycobacteriophages based on phage DS6A – which
only form plaques on MTBC strains – also give reporter signal
from some NTM strains (Mayer et al., 2016), and thus a pre-
infection treatment with PNB remains a reasonable option for
strain discrimination.
Since rapid genotypic tests cannot discriminate between
viable and non-viable cells, the good correlation found between
the number of viable bacteria recovered from sputum and
the number of fluorescent bacilli detected with mCherrybombφ
suggests that this methodology could be a promising tool for a
rapid follow up of patient’s response to antibiotic treatment.
During this study, using mCherrybombφ we identified all
samples carrying RIFR strains after 5 days from sputum
collection. Four of those strains were further classified by
culture as pre-XDR and XDR-TB reflecting the importance of
early detection of this marker. When susceptibility to other
antibiotics was tested with mCherrybombφ in these four isolates,
a good correlation was observed with the results from the
reference proportion method. It is worth noticing that if
enough sample is provided for analysis, susceptibility to any
antibiotic could be tested directly in the recovered sputum sample
based on the incidence of antibiotic resistance in the tested
population.
After WGS of the four pre-XDR and XDR-TB strains, in
most cases we were able to identify mutations that could
explain the observed phenotype. But for one strain that
tested kanamycin resistant with both methods (152748), we
were not able to identify genes that could account for that
profile despite detailed analysis of the sequencing data. This
result highlights the discrepancies that can be found between
genotypic and phenotypic tests (Ocheretina et al., 2014; Ahmad
et al., 2016; Gurbanova et al., 2017). Antibiotic resistance
cannot always be correlated with the presence of mutations
in expected genes (Louw et al., 2009), which is the case
of efflux-mediated resistance (da Silva et al., 2011; Machado
et al., 2018) and also, it has been shown, for example, that
mycobacterial mistranslation has a role in tolerance to the
antibiotic rifampicin due to the generation of gain of function
protein variants where the rpoB gene is unaffected (Javid
et al., 2014). These observations reflect the importance of
rapid methods that evaluate phenotypic resistance in clinical
isolates.
The estimated cost for a mCherrybombφ based diagnostic test
is about USD 2 for the four determinations (48/96 h ±RIF).
Since this is a phenotypic test, susceptibility to any antibiotic
can be evaluated, including those with mechanisms of antibiotic
resistance that cannot be identified using a molecular beacon-
based approach (Rubin, 2018) or when genetic determinants for
antibiotic resistance are not known.
The demonstrated attributes of mCherrybombφ could facilitate
making this methodology an easy, inexpensive and rapid
complementary phenotypic assay for TB diagnosis and DST to
be implemented in moderate risk TB laboratories (World Health
Organization, 2012).
AUTHOR CONTRIBUTIONS
LR, CL, EU, FP, MM, and SP contributed to concept and
design, acquisition of data, data analysis and interpretation, and
drafting the manuscript. ES, DDP, AT, and SN contributed to
sequencing data analysis and interpretation. GH contributed to
data analysis and interpretation, and drafting and revising of the
manuscript. MP contributed to concept and design, data analysis
and interpretation, drafting and revising, and approval of the
manuscript.
FUNDING
This work was funded by ANPCyT PICT2009-009, CONICET
PIP 2011-0222, and ANPCyT PICT2015-3861 to MP. LR and EU
are fellows of CONICET.
ACKNOWLEDGMENTS
We thank Josefina Campos from Instituto Nacional de
Enfermedades Infecciosas, ANLIS, Buenos Aires, Argentina for
sequencing of M. tuberculosis strains 161109, 152748, 16138, and
156324.
Frontiers in Microbiology | www.frontiersin.org 12 July 2018 | Volume 9 | Article 1471
fmicb-09-01471 July 4, 2018 Time: 17:57 # 13
Rondón et al. Fluoromycobacteriophage Analysis of Tuberculosis
REFERENCES
Ahmad, S., Mokaddas, E., Al-Mutairi, N., Eldeen, H. S., and Mohammadi, S. (2016).
Discordance across phenotypic and molecular methods for drug susceptibility
testing of drug-resistant Mycobacterium tuberculosis isolates in a low TB
incidence country. PLoS One 11:e0153563. doi: 10.1371/journal.pone.0153563
Albert, H., Heydenrych, A., Mole, R., Trollip, A., and Blumberg, L. (2001).
Evaluation of FASTPlaque TB-RIF, a rapid, manual test for the determination of
rifampicin resistance from Mycobacterium tuberculosis cultures. Int. J. Tuberc.
Lung Dis. 5, 906–911.
Albert, H., Trollip, A., Seaman, T., and Mole, R. J. (2004). Simple, phage-based
(FASTPlaque) technology to determine rifampicin resistance of Mycobacterium
tuberculosis directly from sputum. Int. J. Tuberc. Lung Dis. 8, 1114–1119.
Albert, H., Trollip, A. P., Seaman, T., Abrahams, C., Mole, R. J., Jordaan, A.,
et al. (2007). Evaluation of a rapid screening test for rifampicin resistance
in re-treatment tuberculosis patients in the Eastern Cape. S. Afr. Med. J. 97,
858–863.
Andrews, S. (2011). FastQC: A Quality Control Tool for High Throughput Sequence
Data. Cambridge: Babraham Institute.
Anthony, R. M., Kolk, A. H., Kuijper, S., and Klatser, P. R. (2006). Light emitting
diodes for auramine o fluorescence microscopic screening of Mycobacterium
tuberculosis. Int. J. Tuberc. Lung Dis. 10, 1060–1062.
Banaiee, N., Bobadilla Del Valle, M., Bardarov, S. Jr., Riska, P. F., Small, P. M.,
Ponce De Leon, A., et al. (2001). Luciferase reporter mycobacteriophages for
detection, identification, and antibiotic susceptibility testing of Mycobacterium
tuberculosis in Mexico. J. Clin. Microbiol. 39, 3883–3888. doi: 10.1128/JCM.39.
11.3883-3888.2001
Bigi, M. M., Lopez, B., Blanco, F. C., Sasiain, M. D., De la Barrera, S., Marti, M. A.,
et al. (2017). Single nucleotide polymorphisms may explain the contrasting
phenotypes of two variants of a multidrug-resistant Mycobacterium tuberculosis
strain. Tuberculosis 103, 28–36. doi: 10.1016/j.tube.2016.12.007
Blakemore, R., Story, E., Helb, D., Kop, J., Banada, P., Owens, M. R., et al. (2010).
Evaluation of the analytical performance of the Xpert MTB/RIF assay. J. Clin.
Microbiol. 48, 2495–2501. doi: 10.1128/JCM.00128-10
Breslauer, D. N., Maamari, R. N., Switz, N. A., Lam, W. A., and Fletcher, D. A.
(2009). Mobile phone based clinical microscopy for global health applications.
PLoS One 4:e6320. doi: 10.1371/journal.pone.0006320
Brossier, F., Sougakoff, W., Aubry, A., Bernard, C., Cambau, E., Jarlier, V., et al.
(2017). Molecular detection methods of resistance to antituberculosis drugs
in Mycobacterium tuberculosis. Méd. Mal. Infect. 47, 340–348. doi: 10.1016/j.
medmal.2017.04.008
Canetti, G., Froman, S., Grosset, J., Hauduroy, P., Langerova, M., Mahler, H. T.,
et al. (1963). Mycobacteria: laboratory methods for testing drug sensitivity and
resistance. Bull. World Health Organ. 29, 565–578.
Chang, K., Lu, W., Wang, J., Zhang, K., Jia, S., Li, F., et al. (2012). Rapid
and effective diagnosis of tuberculosis and rifampicin resistance with Xpert
MTB/RIF assay: a meta-analysis. J. Infect. 64, 580–588. doi: 10.1016/j.jinf.2012.
02.012
Cingolani, P., Platts, A., Wangle, L., Coon, M., Nguyen, T., Wang, L., et al.
(2012). A program for annotating and predicting the effects of single nucleotide
polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain
w1118; iso-2; iso-3. Fly 6, 80–92. doi: 10.4161/fly.19695
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., et al. (1998).
Deciphering the biology of Mycobacterium tuberculosis from the complete
genome sequence. Nature 393, 537–544. doi: 10.1038/31159
Cook, D. E., and Andersen, E. C. (2017). VCF-kit: assorted utilities for the variant
call format. Bioinformatics 33, 1581–1582. doi: 10.1093/bioinformatics/btx011
da Silva, P. E., Von Groll, A., Martin, A., and Palomino, J. C. (2011). Efflux as a
mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol.
Med. Microbiol. 63, 1–9. doi: 10.1111/j.1574-695X.2011.00831.x
Datta, G., Nieto, L. M., Davidson, R. M., Mehaffy, C., Pederson, C., Dobos,
K. M., et al. (2016). Longitudinal whole genome analysis of pre and post drug
treatment Mycobacterium tuberculosis isolates reveals progressive steps to drug
resistance. Tuberculosis 98, 50–55. doi: 10.1016/j.tube.2016.02.004
Daza Bolaños, C. A., Lechinski De Paula, C., Trevizan Guerra, S., Junqueira
Franco, M., and García Ribeiro, M. (2017). Diagnosis of mycobacteria in bovine
milk: an overview. Rev. Inst. Med. Trop. São Paulo 59, 1–13.
de Kantor, I. N., and Barrera, L. (2007). Susceptibility tests to second line drugs and
re-treatment of tuberculosis revisiting early experiences. Medicina 67, 231–237.
Dinnes, J., Deeks, J., Kunst, H., Gibson, A., Cummins, E., Waugh, N., et al.
(2007). Rapid diagnostic tests for the detection of tuberculosis infection. Health
Technol. Assess. 11, 1–196. doi: 10.3310/hta11030
Dobbs, T. E., and Webb, R. M. (2017). Chemotherapy of tuberculosis. Microbiol.
Spectr. 5, 107–119. doi: 10.1128/microbiolspec.TNMI7-0040-2017
Dobner, P., Bretzel, G., Rusch-Gerdes, S., Feldmann, K., Rifai, M., Loscher, T., et al.
(1997). Geographic variation of the predictive values of genomic mutations
associated with streptomycin resistance in Mycobacterium tuberculosis. Mol.
Cell. Probes 11, 123–126. doi: 10.1006/mcpr.1996.0086
Eldholm, V., Monteserin, J., Rieux, A., Lopez, B., Sobkowiak, B., Ritacco, V., et al.
(2015). Four decades of transmission of a multidrug-resistant Mycobacterium
tuberculosis outbreak strain. Nat. Commun. 6:7119. doi: 10.1038/ncomms8119
Eltringham, I. J., Wilson, S. M., and Drobniewski, F. A. (1999). Evaluation of
a bacteriophage-based assay (phage amplified biologically assay) as a rapid
screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and
ciprofloxacin among clinical isolates of Mycobacterium tuberculosis. J. Clin.
Microbiol. 37, 3528–3532.
Faksri, K., Hanchaina, R., Sangka, A., Namwat, W., and Lulitanond, V. (2015).
Development and application of single-tube multiplex real-time PCR for
lineage classi fi cation of Mycobacterium tuberculosis based on large sequence
polymorphism in Northeast Thailand. Tuberculosis 95, 404–410. doi: 10.1016/j.
tube.2015.04.009
Fan, J., Zhang, H., Nguyen, D. T., Lyon, C. J., Mitchell, C. D., Zhao, Z., et al.
(2017). Rapid diagnosis of new and relapse tuberculosis by quantification of a
circulating antigen in HIV-infected adults in the Greater Houston metropolitan
area. BMCMed. 15:188. doi: 10.1186/s12916-017-0952-z
Ford, M. E., Stenstrom, C., Hendrix, R. W., and Hatfull, G. F. (1998).
Mycobacteriophage TM4: genome structure and gene expression. Tuber. Lung
Dis. 79, 63–73. doi: 10.1054/tuld.1998.0007
Galarza, M., Tarazona, D., Borda, V., Agapito, J. C., and Guio, H. (2014). Evidence
of clonal expansion in the genome of a multidrug-resistant Mycobacterium
tuberculosis clinical isolate from Peru. Genome Announc. 2, 2013–2014. doi:
10.1128/genomeA.00089-14
Garberi, J., Labrador, J., Garberi, F., Garberi, J. E., Peneipil, J., Garberi, M.,
et al. (2011). Diagnosis of Mycobacterium tuberculosis using molecular biology
technology. Asian Pac. J. Trop. Biomed. 1, 89–93. doi: 10.1016/S2221-1691(11)
60002-6
Glaziou, P., Falzon, D., Floyd, K., and Raviglione, M. (2013). Global epidemiology
of tuberculosis. Semin. Respir. Crit. Care Med. 34, 3–16. doi: 10.1055/s-0032-
1333467
Gurbanova, E., Mehdiyev, R., Blondal, K., Tahirli, R., Mirzayev, F., Hillemann, D.,
et al. (2017). Mitigation of discordant rifampicin-susceptibility results obtained
by Xpert Mycobacterium tuberculosis/ rifampicin and Mycobacterium growth
indicator tube. Microb. Drug Resist. 23, 1045–1052. doi: 10.1089/mdr.2016.0149
Hatfull, G. F. (2010). Mycobacteriophages: genes and genomes. Annu. Rev.
Microbiol. 64, 331–356. doi: 10.1146/annurev.micro.112408.134233
Hatfull, G. F. (2012). The secret lives of mycobacteriophages. Adv. Virus Res. 82,
179–288. doi: 10.1016/B978-0-12-394621-8.00015-7
Hazbón, M. H. (2004). Recent advances in molecular methods for early diagnosis
of tuberculosis and drug-resistant tuberculosis. Biomedica 24, 149–162. doi:
10.7705/biomedica.v24iSupp1.1314
Hemvani, N., Patidar, V., and Chitnis, D. S. (2012). A simple and economical
in-house phage technique for the rapid detection of rifampin, isoniazid,
ethambutol, streptomycin, and ciprofloxacin drug resistance in Mycobacterium
tuberculosis, directly on decontaminated sputum samples. Int. J. Infect. Dis. 16,
e332–e336. doi: 10.1016/j.ijid.2011.12.016
Huerta-cepas, J., Serra, F., and Bork, P. (2016). ETE 3: reconstruction, analysis,
and visualization of phylogenomic data. Mol. Biol. Evol. 33, 1635–1638. doi:
10.1093/molbev/msw046
Jacobs, W. R. Jr., Barletta, R. G., Udani, R., Chan, J., Kalkut, G., Sosne, G., et al.
(1993). Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis
by means of luciferase reporter phages. Science 260, 819–822. doi: 10.1126/
science.8484123
Jain, P., Hartman, T. E., Eisenberg, N., O’Donnell, M. R., Kriakov, J., Govender, K.,
et al. (2012). ϕ(2) GFP10, a high-intensity fluorophage, enables detection and
Frontiers in Microbiology | www.frontiersin.org 13 July 2018 | Volume 9 | Article 1471
fmicb-09-01471 July 4, 2018 Time: 17:57 # 14
Rondón et al. Fluoromycobacteriophage Analysis of Tuberculosis
rapid drug susceptibility testing of Mycobacterium tuberculosis directly from
sputum samples. J. Clin. Microbiol. 50, 1362–1369. doi: 10.1128/JCM.06192-11
Javid, B., Sorrentino, F., Toosky, M., Zheng, W., Pinkham, J. T., Jain, N., et al.
(2014). Mycobacterial mistranslation is necessary and sufficient for rifampicin
phenotypic resistance. Proc. Natl. Acad. Sci. U.S.A. 111, 1132–1137. doi: 10.
1073/pnas.1317580111
Kiraz, N., Et, L., Akgun, Y., Kasifoglu, N., and Kiremitci, A. (2007). Rapid detection
of Mycobacterium tuberculosis from sputum specimens using the FAST Plaque
TB test. Int. J. Tuberc. Lung Dis. 11, 904–908.
Lee, A. S., Lim, I. H., Tang, L. L., Telenti, A., and Wong, S. Y. (1999). Contribution
of kasA analysis to detection of isoniazid- resistant Mycobacterium tuberculosis
in Singapore. Antimicrob. Agents Chemother. 43, 2087–2089.
Li, H., and Durbin, R. (2010). Fast and accurate long-read alignment with Burrows-
Wheeler transform. Bioinformatics 26, 589–595. doi: 10.1093/bioinformatics/
btp698
López-Hernández, Y., Patiño-Rodríguez, O., García-Orta, S. T., and Pinos-
Rodríguez, J. M. (2016). Mass Spectrometry applied to the identification of
M. tuberculosis and biomarkers discovery. J. Appl. Microbiol. 121, 1485–1497.
doi: 10.1111/jam.13323
Louw, G. E., Warren, R. M., van Helden, P. D., and Victor, T. C. (2009). Rv2629
191A/C nucleotide change is not associated with rifampicin resistance in
Mycobacterium tuberculosis. Clin. Chem. Lab. Med. 47, 500–501. doi: 10.1515/
CCLM.2009.111
Machado, D., Perdigão, J., Portugal, I., Pieroni, M., Silva, P. A., Couto, I., et al.
(2018). Activity differentially modulates the levels of isoniazid and rifampicin
resistance among multidrug resistant and monoresistant Mycobacterium
tuberculosis strains. Antibiotics 7:18. doi: 10.3390/antibiotics7010018
Madico, G., Mpeirwe, M., White, L., Vinhas, S., Orr, B., Orikiriza, P., et al. (2016).
Detection and quantification of Mycobacterium tuberculosis in the sputum of
culture-negative HIV-infected pulmonary tuberculosis suspects: a proof-of-
concept study. PLoS One 11:e0158371. doi: 10.1371/journal.pone.0158371
Madison, B., Robinson-Dunn, B., George, I., Gross, W., Lipman, H., Metchock, B.,
et al. (2002). Multicenter evaluation of ethambutol susceptibility testing of
Mycobacterium tuberculosis by agar proportion and radiometric methods.
J. Clin. Microbiol. 40, 3976–3979. doi: 10.1128/JCM.40.11.3976-3979.2002
Marais, B. J., Brittle, W., Painczyk, K., Hesseling, A. C., Beyers, N., Wasserman, E.,
et al. (2008). Use of light-emitting diode fluorescence microscopy to detect
acid-fast bacilli in sputum. Clin. Infect. Dis. 47, 203–207. doi: 10.1086/589248
Martin, A., Fissette, K., Varaine, F., Portaels, F., and Palomino, J. C. (2009).
Thin layer agar compared to BACTEC MGIT 960 for early detection of
Mycobacterium tuberculosis. J. Microbiol. Methods 78, 107–108. doi: 10.1016/
j.mimet.2009.05.001
Mayer, O., Jain, P., Weisbrod, T. R., Biro, D., Ho, L., Jacobs-Sera, D., et al. (2016).
Fluorescent reporter DS6A mycobacteriophages reveal unique variations in
infectibility and phage production in mycobacteria. J. Bacteriol. 198, 3220–3232.
doi: 10.1128/JB.00592-16
Mboowa, G., Namaganda, C., and Ssengooba, W. (2014). Rifampicin resistance
mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis
clinical isolates using Xpert R© MTB/RIF in Kampala, Uganda: a retrospective
study. BMC Infect. Dis. 14:481. doi: 10.1186/1471-2334-14-481
Mckenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A.,
et al. (2010). The genome analysis toolkit: a MapReduce framework for
analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303.
doi: 10.1101/gr.107524.110
Mokaddas, E., Ahmad, S., Eldeen, H. S., and Al-Mutairi, N. (2015). Discordance
between Xpert MTB/RIF assay and bactec MGIT 960 culture system for
detection of rifampin-resistant Mycobacterium tuberculosis isolates in a country
with a low tuberculosis (TB) incidence. J. Clin. Microbiol. 53, 1351–1354. doi:
10.1128/JCM.03412-14
Mole, R., Trollip, A., Abrahams, C., Bosman, M., and Albert, H. (2007). Improved
contamination control for a rapid phage-based rifampicin resistance test for
Mycobacterium tuberculosis. J. Med. Microbiol. 56, 1334–1339. doi: 10.1099/
jmm.0.46936-0
Naveen, G., and Peerapur, B. V. (2012). Comparison of the Lowenstein-Jensen
medium, the middlebrook 7H10 medium and MB/BACT for the isolation of
Mycobacterium tuberculosis (MTB) from clinical specimens. J. Clin. Diagn. Res.
6, 1704–1709. doi: 10.7860/JCDR/2012/4603.2635
Ocheretina, O., Escuyer, V. E., Mabou, M. M., Royal-Mardi, G., Collins, S., Vilbrun,
S. C., et al. (2014). Correlation between genotypic and phenotypic testing for
resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti:
investigation of cases with discrepant susceptibility results. PLoS One 9:e90569.
doi: 10.1371/journal.pone.0090569
O’Donnell, M. R., Pym, A., Jain, P., Munsamy, V., Wolf, A., Karim, F., et al. (2015).
A novel reporter phage to detect tuberculosis and rifampin resistance in a high-
HIV-burden population. J. Clin. Microbiol. 53, 2188–2194. doi: 10.1128/JCM.
03530-14
Okamoto, S., Tamaru, A., Nakajima, C., Nishimura, K., Tanaka, Y., Tokuyama, S.,
et al. (2007). Loss of a conserved 7-methylguanosine modification in 16S
rRNA confers low-level streptomycin resistance in bacteria. Mol. Microbiol. 63,
1096–1106. doi: 10.1111/j.1365-2958.2006.05585.x
Piuri, M., Jacobs, W. R. Jr., and Hatfull, G. F. (2009). Fluoromycobacteriophages for
rapid, specific, and sensitive antibiotic susceptibility testing of Mycobacterium
tuberculosis. PLoS One 4:e4870. doi: 10.1371/journal.pone.0004870
Radusky, L., Defelipe, L. A., Lanzarotti, E., Luque, J., Barril, X., Marti, M. A., et al.
(2014). TuberQ: a Mycobacterium tuberculosis protein druggability database.
Database 2014:bau035. doi: 10.1093/database/bau035
Rahman, A., Sahrin, M., Afrin, S., Earley, K., Ahmed, S., Raman, S. M., et al.
(2016). Comparison of Xpert MTB/RIF assay and GenoType MTBDR plus
DNA probes for detection of mutations associated with rifampicin resistance in
Mycobacterium tuberculosis. PLoS One 11:e0152694. doi: 10.1371/journal.pone.
0152694
Riska, P. F., Jacobs, W. R. Jr., Bloom, B. R., McKitrick, J., and Chan, J.
(1997). Specific identification of Mycobacterium tuberculosis with the luciferase
reporter mycobacteriophage: use of p-nitro-alpha-acetylamino-beta-hydroxy
propiophenone. J. Clin. Microbiol. 35, 3225–3231.
Rondón, L., Piuri, M., Jacobs, W. R. Jr., De Waard, J., Hatfull, G. F., and Takiff, H. E.
(2011). Evaluation of fluoromycobacteriophages for detecting drug resistance
in Mycobacterium tuberculosis. J. Clin. Microbiol. 49, 1838–1842. doi: 10.1128/
JCM.02476-10
Rubin, E. J. (2018). TB diagnosis from the Dark Ages to fluorescence. Nat.
Microbiol. 3, 268–269. doi: 10.1038/s41564-018-0118-6
Rufai, S. B., Kumar, P., Singh, A., Prajapati, S., Balooni, V., and Singh, S. (2014). of
Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant
Mycobacterium tuberculosis. J. Clin. Microbiol. 52, 1846–1852. doi: 10.1128/
JCM.03005-13
Sales, M. L., Fonseca Junior, A. A., Orzil, L., Alencar, A. P., Silva, M. R., Issa, M. A.,
et al. (2015). Validation of a real-time PCR assay for the molecular identification
of Mycobacterium tuberculosis. Braz. J. Microbiol. 45, 1363–1369.
Salzer, H. J., Wassilew, N., Kohler, N., Olaru, I. D., Gunther, G., Herzmann, C.,
et al. (2016). Personalized medicine for chronic respiratory infectious diseases:
tuberculosis, nontuberculous mycobacterial pulmonary diseases, and chronic
pulmonary aspergillosis. Respiration 92, 199–214. doi: 10.1159/000449037
Sandgren, A., Strong, M., Muthukrishnan, P., Weiner, B. K., Church, G. M., and
Murray, M. B. (2009). Tuberculosis drug resistance mutation database. PLoS
Med. 6:e2. doi: 10.1371/journal.pmed.1000002
Schmieder, R., and Edwards, R. (2011). Quality control and preprocessing
of metagenomic datasets. Bioinformatics 27, 863–864. doi: 10.1093/
bioinformatics/btr026
Shakoor, S., Ahsan, T., Jabeen, K., Raza, M., and Hasan, R. (2010). Use
of p-nitrobenzoic acid in 7H10 agar for identification of Mycobacterium
tuberculosis complex: a field study. Int. J. Tuberc. Lung Dis. 14, 1644–1646.
Sharma, B., Pal, N., Malhotra, B., and Vyas, L. (2010). Evaluation of a rapid
differentiation test for Mycobacterium tuberculosis from other mycobacteria by
selective inhibition with p-nitrobenzoic acid using MGIT 960. J. Lab. Phys. 2,
89–92. doi: 10.4103/0974-2727.72157
Sreevatsan, S., Stockbauer, K. E., Pan, X., Kreiswirth, B. N., Moghazeh, S. L., Jacobs,
W. R. Jr., et al. (1997). Ethambutol resistance in Mycobacterium tuberculosis:
critical role of embB mutations. Antimicrob. Agents Chemother. 41, 1677–1681.
Sulis, G., Centis, R., Sotgiu, G., D’Ambrosio, L., Pontali, E., Spanevello, A., et al.
(2016). Recent developments in the diagnosis and management of tuberculosis.
NPJ Prim. Care Respir. Med. 26:16078. doi: 10.1038/npjpcrm.2016.78
Teo, J., Jureen, R., Chiang, D., Chan, D., and Lin, R. (2011). Comparison of two
nucleic acid amplification assays, the Xpert MTB/RIF assay and the amplified
Mycobacterium tuberculosis direct assay, for detection of Mycobacterium
Frontiers in Microbiology | www.frontiersin.org 14 July 2018 | Volume 9 | Article 1471
fmicb-09-01471 July 4, 2018 Time: 17:57 # 15
Rondón et al. Fluoromycobacteriophage Analysis of Tuberculosis
tuberculosis in respiratory and nonrespiratory specimens. J. Clin. Microbiol. 49,
3659–3662. doi: 10.1128/JCM.00211-11
The R Foundation (2018). The R Project for Statistical Computing. Available at:
https://www.r-project.org/
Urdániz, E., Rondón, L., Martí, M. A., Hatfull, G. F., and Piuri, M. (2016).
Rapid whole-cell assay of antitubercular drugs using second-generation
fluoromycobacteriophages. Antimicrob. Agents Chemother. 60, 3253–3256. doi:
10.1128/AAC.03016-15
van Soolingen, D., Hermans, P. W., de Haas, P. E., Soll, D. R., and van Embden,
J. D. (1991). Occurrence and stability of insertion sequences in Mycobacterium
tuberculosis complex strains: evaluation of an insertion sequence-dependent
DNA polymorphism as a tool in the epidemiology of tuberculosis. J. Clin.
Microbiol. 29, 2578–2586.
Venables, W. N., and Ripley, B. D. (2002). Modern Applied Statistics with S.
New York, NY: Springer. doi: 10.1007/978-0-387-21706-2
Wassilew, N., Hoffmann, H., Andrejak, C., and Lange, C. (2016). Pulmonary
disease caused by non-tuberculous mycobacteria. Respiration 91, 386–402. doi:
10.1159/000445906
Watterson, S. A., Wilson, S. M., Yates, M. D., and Drobniewski, F. A.
(1998). Comparison of three molecular assays for rapid detection of
rifampin resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 36,
1969–1973.
Weldu, Y., Asrat, D., Woldeamanuel, Y., and Hailesilasie, A. (2013). Comparative
evaluation of a two-reagent cold stain method with Ziehl-Nelseen method for
pulmonary tuberculosis diagnosis. BMC Res. Notes 6:323. doi: 10.1186/1756-
0500-6-323
WHO (2011). Rapid Implementation of the Xpert MTB/RIF Diagnostic
Test. Available at: http://apps.who.int/iris/bitstream/10665/44593/1/
9789241501569_eng.pdf
WHO (2016). The Shorter MDR-TB Regimen. Available at: http://www.who.int/tb/
Short_MDR_regimen_factsheet.pdf
WHO (2017). TDR 2016 Annual Report: Health Research Impact that
Lasts. Available at: http://apps.who.int/iris/bitstream/10665/255775/1/
9789241512664-eng.pdf
Wilson, S. M., al-Suwaidi, Z., McNerney, R., Porter, J., and Drobniewski, F.
(1997). Evaluation of a new rapid bacteriophage-based method for the drug
susceptibility testing of Mycobacterium tuberculosis. Nat. Med. 3, 465–468. doi:
10.1038/nm0497-465
World Health Organization (2012). Tuberculosis Laboratory Biosafety Manual.
Tuberc Lab Biosaf Man. Available at: http://www.ncbi.nlm.nih.gov/pubmed/
24404640
Yu, X., Gu, Y., Jiang, G., Ma, Y., Zhao, L., Sun, Z., et al. (2016). Evaluation
of a high-intensity green fluorescent protein fluorophage method for drug-
resistance diagnosis in tuberculosis for isoniazid, rifampin, and streptomycin.
Front. Microbiol. 7:922. doi: 10.3389/fmicb.2016.00922
Zhu, C., Cui, Z., Zheng, R., Yang, H., Jin, R., Qin, L., et al. (2011). A multi-center
study to evaluate the performance of phage amplified biologically assay for
detecting TB in sputum in the pulmonary TB patients. PLoS One 6:e24435.
doi: 10.1371/journal.pone.0024435
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Rondón, Urdániz, Latini, Payaslian, Matteo, Sosa, Do Porto,
Turjanski, Nemirovsky, Hatfull, Poggi and Piuri. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Microbiology | www.frontiersin.org 15 July 2018 | Volume 9 | Article 1471
